Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma

被引:28
作者
Hoar, FJ
Chaudhri, S
Wadley, MS
Stonelake, PS
机构
[1] City Hosp, Dept Surg, Birmingham B18 7QH, W Midlands, England
[2] City Hosp, Dept Pathol, Birmingham B18 7QH, W Midlands, England
关键词
breast neoplasms; VEGF-C; c-erbB2; lymphatic metastasis; bone marrow;
D O I
10.1016/S0959-8049(03)00382-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Vascular endothelial growth factor C (VEGF-C) has angiogenic and lymphangiogenic properties and is associated with the development of lymphatic metastases in a number of epithelial malignancies. The aim of this study was to determine VEGF-C protein expression in a series of breast carcinomas and correlate this with axillary lymph node (LN) metastases, the presence of lympho-vascular invasion (LVI), bone marrow micro-metastases (BMM) and other clinico-pathological data including oestrogen receptor (ER) and c-erbB2 status. VEGF-C expression was determined by immunohistochemistry (IHC) in 51 tumours. ER and c-erbB2 were also assessed by IHC. Bone marrow analysis was performed using a combination of immunomagnetic separation and immunocytochemistry. Overall, 30/51 (59%) of the tumours were positive for VEGF-C. There was no significant correlation between VEGF-C expression and LN status, LVI, BMM, tumour size, grade or ER status. However, there was an association between c-erbB2 and VEGF-C expression (P = 0.013). The correlation between VEGF-C and c-erbB2 suggests a functional relationship and may, in part, explain the aggressive phenotype associated with c-erbB2-positive tumours. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1698 / 1703
页数:6
相关论文
共 34 条
[1]
Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues [J].
Akagi, K ;
Ikeda, Y ;
Miyazaki, M ;
Abe, T ;
Kinoshita, J ;
Maehara, Y ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :887-891
[2]
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[3]
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[4]
Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal [J].
Diel, IJ ;
Kaufmann, M ;
Costa, SD ;
Holle, R ;
vonMinckwitz, G ;
Solomayer, EF ;
Kaul, S ;
Bastert, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1652-1658
[5]
Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
[6]
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[7]
Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients [J].
Fox, SB ;
Leek, RD ;
Bliss, J ;
Mansi, JL ;
Gusterson, B ;
Gatter, KC ;
Harris, AL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (14) :1044-1049
[8]
Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma [J].
Furudoi, A ;
Tanaka, S ;
Haruma, K ;
Kitadai, Y ;
Yoshihara, M ;
Chayama, K ;
Shimamoto, F .
ONCOLOGY, 2002, 62 (02) :157-166
[9]
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma [J].
Gasparini, G ;
Toi, M ;
Gion, M ;
Verderio, P ;
Dittadi, R ;
Hanatani, M ;
Matsubara, I ;
Vinante, O ;
Bonoldi, E ;
Boracchi, P ;
Gatti, C ;
Suzuki, H ;
Tominaga, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (02) :139-147
[10]
Gunningham SP, 2000, CLIN CANCER RES, V6, P4278